水飞蓟宾治疗对非酒精性脂肪性肝病患者转氨酶影响的Meta分析

Effect of silibinin on liver aminotransferases in patients with nonalcoholic fatty liver disease: A meta-analysis

目的对水飞蓟宾治疗对非酒精性脂肪性肝病患者转氨酶影响的文献进行Meta分析,探讨水飞蓟宾对脂肪肝患者的护肝作用。方法计算机及手工检索知网、万方、维普网、Sinomed、Pubmed、Medline、Embase、ScienceDirect等数据库,收集关于水飞蓟宾治疗非酒精性脂肪性肝病患者的随机临床对照试验文献,根据纳入排除标准筛选后评价文献质量,并提取数据,采用RevMan 5. 3软件进行Meta分析。结果共纳入8篇文献,共计665例患者,在使用水飞蓟宾治疗8周～3个月后,可明显降低NAFLD患者血清ALT水平[加权均数差(WMD)=-11. 60,95%可信区间(95%CI):-18. 68～-4. 51,P=0. 001]和AST水平[WMD=-11. 56,95%CI:-16. 93～-6. 18,P <0. 001]。结论水飞蓟宾可明确降低非酒精性脂肪性肝病患者血清ALT、AST水平。

Objective To conduct a meta-analysis of the articles on the effect of silibinin on aminotransferases in patients with nonalcoholic fatty liver disease (NAFLD),and to investigate the liver-protecting effect of silibinin in patients with NAFLD. Methods CNKI,Wanfang Data,VIP,SinoMed,PubMed,MEDLINE,Embase,and ScienceDirect were searched for randomized controlled trials (RCTs) on the treatment of NAFLD patients with silibinin,The articles were screened according to inclusion and exclusion criteria,and then quality assessment and data extraction were performed. RevMan 5.3 was used to perform the meta-analysis. Results A total of 8 articles with 665 patients were included. After 8 weeks to 3 months of silibinin treatment,there were significant reductions in the serum levels of alanine aminotransferase (ALT)(weighted mean difference [WMD]=-11.60,95% confidence interval [CI]:-18.68 to -4.51,P =0.001) and aspartate aminotransferase (AST)(WMD=-11.56,95% CI:-16.93 to -6.18,P <0.001). Conclusion Silibinin can significantly reduce the serum levels of ALT and AST in patients with NAFLD.